The €13.25-a-share deal represents a 53 per cent premium on Mediq’s Friday closing price and has been unanimously recommended to shareholders by the company’s management and supervisory boards.
Templeton Investment Counsel and Silchester International Investors, which hold more than 20 per cent of Mediq’s outstanding shares, have already irrevocably confirmed their support for the buyout.
Mediq said Advent’s ownership would help support the company’s existing growth strategy by providing financing, expertise and support for capital expenditure, investments and acquisitions.
Advent is no stranger to healthcare deals. In April the firm struck one of the largest Indian healthcare deals of recent years with a $105m investment in CARE Hospitals, while last October invested an undisclosed amount in warsaw-based American Heart of Poland.
Copyright © 2012 AltAssets